Home
/
Royalty Pharma plc
/
Financials
/
Quarterly
Royalty Pharma plc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Royalty Pharma plc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$609.29M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$578.67M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$568.25M
May 8, 2025
Q3
2025
Sep 30, 2024
$564.69M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$537.27M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$567.98M
May 8, 2025
Q3
2024
Sep 30, 2023
$536.31M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$538.20M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$683.97M
May 9, 2024
Q3
2023
Sep 30, 2022
$573.46M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$535.96M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$562.05M
May 9, 2023
Q3
2022
Sep 30, 2021
$585.77M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$554.96M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$573.03M
May 5, 2022
Q3
2021
Sep 30, 2020
$538.40M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$510.93M
Aug 11, 2021
Q1
2021
Mar 31, 2020
$500.88M
May 11, 2021
Q3
2020
Sep 30, 2019
$464.28M
Nov 12, 2020
Q2
2020
Jun 30, 2019
$457.61M
Aug 12, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$288.22M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$30.18M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$238.35M
May 8, 2025
Q3
2025
Sep 30, 2024
$543.99M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$102.00M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$4.78M
May 8, 2025
Q3
2024
Sep 30, 2023
$72.11M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$227.63M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$340.76M
May 9, 2024
Q3
2023
Sep 30, 2022
$142.65M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$304.50M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$51.76M
May 9, 2023
Q3
2022
Sep 30, 2021
$101.93M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$440.78M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$69.12M
May 5, 2022
Q3
2021
Sep 30, 2020
$290.63M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$442.07M
Aug 11, 2021
Q1
2021
Mar 31, 2020
$71.24M
May 11, 2021
Q3
2020
Sep 30, 2019
$408.98M
Nov 12, 2020
Q2
2020
Jun 30, 2019
$151.71M
Aug 12, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$427.16M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$209.80M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$534.18M
May 8, 2025
Q3
2025
Sep 30, 2024
$735.07M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$269.63M
Aug 6, 2025
Q1
2025
Mar 31, 2024
($73.77M)
May 8, 2025
Q3
2024
Sep 30, 2023
$151.44M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$248.84M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$478.97M
May 9, 2024
Q3
2023
Sep 30, 2022
$192.21M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$377.79M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$219.72M
May 9, 2023
Q3
2022
Sep 30, 2021
$303.05M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$744.95M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$229.30M
May 5, 2022
Q3
2021
Sep 30, 2020
$510.57M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$409.35M
Aug 11, 2021
Q1
2021
Mar 31, 2020
$361.43M
May 11, 2021
Q3
2020
Sep 30, 2019
$532.50M
Nov 12, 2020
Q2
2020
Jun 30, 2019
$327.86M
Aug 12, 2020